6 Biotech Investors in London — 6 Currently Deploying
Updated
Funds (6)
Back European founders with strong qualities (not CV/pedigree) building businesses for a better human future, assessed on characteristics like productivity, grit, and commercial ac…
European venture with Silicon Valley mindset; deliberately anti-thematic, backing founders building in non-obvious market categories early with focus on US market expansion and max…
Equitable venture capital model where every founder backed becomes a co-owner of the fund. Early-stage investments in mission-driven, pre-seed and seed founders who are outliers, o…
Partner with exceptional people to help them realize their full potential across pre-seed, seed, growth, and public market stages through long-term founder relationships.
Backing mission-driven, outlier founders at pre-seed and seed stage across UK, Europe and North America through generalist and institutional thesis-driven funds.
Which of these Biotech funds actually fits your startup?
DryPowder's AI matching ranks all 6 by thesis fit, check size, and deployment status.
Get my fund matches →Related investor lists
Frequently asked questions
How many biotech investors are actively deploying right now?
DryPowder tracks 6 biotech funds. Of these, 6 are currently deploying capital based on recent fund closes, portfolio activity, and partner signals. Use DryPowder's fund matching to see which ones fit your specific startup.
What check size do biotech VCs write?
Among 6 biotech funds on DryPowder, check sizes run from $100K–$2M. Ranges vary by fund size, vintage, and whether the fund leads rounds. Each fund profile shows check size detail and lead preference.
How do I get a meeting with a biotech VC?
A warm intro is still the fastest path. Most biotech VCs on DryPowder do accept cold outreach or direct applications, but response rates vary widely by fund. Before reaching out, use DryPowder's AI matching to get a fit score and specific talking points. Founders who lead with thesis-aligned framing get significantly better response rates than those sending the same deck to every fund on a list.
What do biotech VCs look for beyond a good deck?
Most biotech investors evaluate three things before reading your deck in detail: your background in the space, whether they have seen the problem from multiple portfolio companies, and whether anyone they trust vouches for you. After that, the deck needs to show market size, a clear problem-solution fit specific to biotech, and early evidence of customer demand. Thesis alignment matters more in biotech than in generalist investing because these funds see a high volume of pitches in the same space.
How many biotech investors should I be talking to at once?
Most fundraisers recommend a parallel process: identify 20-40 target investors but approach your highest-fit funds first. Of the 6 biotech funds currently deploying, not all will match your specific stage and sector. Use fund matching to find your top 10-15, approach those first, collect feedback, then go wider. Going to every fund simultaneously without qualifying first burns bridges and dilutes the urgency that helps close a round.
How is DryPowder different from building a VC list on LinkedIn or Crunchbase?
The fund list you build on LinkedIn or Crunchbase is roughly the same list every other founder is building. DryPowder adds three things a manual search cannot: deployment signals (which funds have recently closed new vehicles and are actively writing checks), AI thesis matching (which of the 6 biotech funds actually fits your specific startup, ranked by fit), and verified partner contact details. The goal is 15 targeted, thesis-aligned pitches instead of 150 generic ones.
How DryPowder compares
See all tool comparisons → · best alternatives by platform →